BGNE - BeiGeneAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $292.75 | Open | $294.48 |
| Volume | 19.5K | Market Cap | 28.018B |
| Yield | Last Dividend |
| BeiGene's Zanubrutinib Fails To Meet Eff... | 04/08/21 |
| BeiGene Ltd (NASDAQ: BGNE ) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supp... | |
| BeiGene Initiates Phase 1 Clinical Trial... | 03/10/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focus... | |
| BeiGene Announces Acceptance of a Supple... | 03/05/21 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focus... | |
| BeiGene Announces Closing of Collaborati... | 02/26/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Closing of Collaboration with Novartis to Develop & Commercialize Anti-... | |
| BeiGene Reports Fourth Quarter and Full ... | 02/25/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focus... | |
| BeiGene Announces U.S. FDA Acceptance of... | 02/17/21 |
| CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRU... | |
| The Daily Biotech Pulse: DermTech Soars ... | 02/11/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X... | |
| BeiGene Announces Positive Topline Resul... | 01/27/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamou... | |
| The Daily Biotech Pulse: Novartis Misses... | 01/26/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abb... | |
| EUSA Pharma and BeiGene Announce Accepta... | 01/25/21 |
| HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) ... | |
| China National Medical Products Administ... | 01/13/21 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous n... | |
| Why BeiGene, T2 Biosystems And Amneal Ar... | 01/12/21 |
| BeiGene (NASDAQ: BGNE ) shares are trading higher ??? Full story available on Benzinga.com | |
| The Daily Biotech Pulse: GSK, Vir To Sta... | 01/12/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X... | |
| BeiGene Announces Collaboration with Nov... | 01/11/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize... | |
| Novartis expands Oncology pipeline with ... | 01/11/21 |
| Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and??? | |
| Strand Therapeutics and BeiGene Enter in... | 01/11/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developi... | |
| BeiGene Announces Inclusion of Three Inn... | 12/27/20 |
| BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China Nationa... | |
| BeiGene Announces the Approval in China ... | 12/07/20 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO?? (blinatumomab) for injection has been approved in China... | |
| BeiGene Presents Clinical Data on BRUKIN... | 12/07/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malig... | |
| BeiGene Announces Data on BRUKINSA?? (Za... | 12/06/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic ly... | |
| BeiGene Launches Proposed Public Offerin... | 12/01/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focus... | |
| Zymeworks Announces Expansion of Zanidat... | 12/01/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe... | |
| BeiGene Announces the Approval of XGEVA?... | 11/19/20 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA?? (denosumab) in China. | |
| BeiGene (NASDAQ:BGNE) Price Target Raise... | 11/19/20 |
| BeiGene (NASDAQ:BGNE) had its price target hoisted by research analysts at SVB Leerink from $240.00 to $327.00 in a note issued to investors on Thursd... | |
| BeiGene Announces that RATIONALE 303 Tri... | 11/17/20 |
| CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung ... | |
| EUSA Pharma and BeiGene Announce Accepta... | 11/09/20 |
| HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160)... | |
| BeiGene Reports Third Quarter 2020 Finan... | 11/05/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene reports recent business highlights, anticipated upcoming milestones and financial... | |
| BeiGene Announces Data on BRUKINSA?? (Za... | 11/05/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA?? (zanubrutinib) and tislelizumab to be presented at th... | |
| Here's how 9 leading drugmakers are raci... | 10/27/20 |
| Summary List Placement In the sprint for an effective coronavirus treatment, several of the biggest drugmakers in the world have all landed on the sam... | |
| Insider Selling: Beigene Ltd (NASDAQ:BGN... | 10/23/20 |
| Beigene Ltd (NASDAQ:BGNE) insider Xiaodong Wang sold 5,000 shares of the firm???s stock in a transaction on Friday, October 16th. The stock was sold a... | |
| Strong Buy rating | 02/18/21 |
| Cowen & Co. maintains Outperform rating and raises Price Target from $348.00 to $429.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| FEAT. MIGUEL | JOHN KROLIKOWSKI JR | 81.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
